ONC vs RPRX
BeOne Medicines AG and Royalty Pharma plc, both Healthcare
Royalty Pharma plc is the larger company at $31B against $29B. Over the past year RPRX returned +59% against +5.9% for ONC.
| Figure | ONC | RPRX |
|---|---|---|
| Last close | $354 | $56.90 |
| Market cap | $29B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 30.3 |
| 1-year return | +5.9% | +59% |
| 5-year return | -4.0% | +61% |
| RyuScoresector-relative, 1–10 | n/a | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
BeOne Medicines AG
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.